As part of our 2015 ASCO Annual Meeting coverage, we discussed immunotherapy combinations in advanced melanoma patients with Michael A. Postow, MD.
ASCO 2015 Melanoma
Updated results from the coBRIM trial show that a BRAF/MEK inhibitor combination continues to provide clinical benefit in BRAF-positive metastatic melanoma.
Data from the KEYNOTE-001 study showed that the anti–PD-1 antibody pembrolizumab produces durable responses in metastatic melanoma patients.
Due to the genetic heterogeneity observed in tumors of melanoma patients who developed resistance to BRAF inhibitors, assessing mechanisms of resistance has minimal potential to inform further treatment decisions.
The anti–PD-1 antibody nivolumab alone or in combination with ipilimumab increased progression-free survival in treatment-naïve metastatic melanoma patients.
Performing a complete lymph node dissection does not improve survival for melanoma patients who underwent a sentinel node biopsy.